Madrigal Pharmaceuticals (MDGL) PT Set at $200.00 by Oppenheimer

Share on StockTwits

Oppenheimer set a $200.00 target price on Madrigal Pharmaceuticals (NASDAQ:MDGL) in a research report report published on Tuesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on MDGL. Goldman Sachs Group cut shares of Madrigal Pharmaceuticals from a buy rating to a neutral rating and set a $314.00 price target on the stock. in a report on Monday, August 6th. Zacks Investment Research cut shares of Madrigal Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, August 29th. Citigroup assumed coverage on shares of Madrigal Pharmaceuticals in a report on Tuesday, September 4th. They issued a buy rating and a $340.00 price target on the stock. BidaskClub raised shares of Madrigal Pharmaceuticals from a strong sell rating to a sell rating in a report on Wednesday, September 12th. Finally, Cowen reaffirmed a buy rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 7th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $297.63.

Madrigal Pharmaceuticals stock opened at $113.04 on Tuesday. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -44.50 and a beta of 1.44. Madrigal Pharmaceuticals has a 52 week low of $77.00 and a 52 week high of $325.98.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). On average, sell-side analysts forecast that Madrigal Pharmaceuticals will post -2.19 earnings per share for the current year.

In other Madrigal Pharmaceuticals news, CEO Paul A. Friedman acquired 4,000 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Monday, November 19th. The stock was acquired at an average cost of $124.00 per share, for a total transaction of $496,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Fred B. Craves acquired 2,000 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Monday, November 19th. The stock was acquired at an average price of $124.69 per share, with a total value of $249,380.00. The disclosure for this purchase can be found here. Insiders own 56.70% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new position in Madrigal Pharmaceuticals in the 2nd quarter valued at approximately $124,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Madrigal Pharmaceuticals in the 2nd quarter valued at approximately $140,000. Public Employees Retirement Association of Colorado purchased a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at approximately $157,000. Stevens Capital Management LP purchased a new position in Madrigal Pharmaceuticals in the 2nd quarter valued at approximately $231,000. Finally, Pacer Advisors Inc. purchased a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at approximately $231,000. Institutional investors and hedge funds own 55.54% of the company’s stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

Recommended Story: Cost of equity and a company’s balance sheet

Analyst Recommendations for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.